1. PPAR-gamma agonist rosiglitazone attenuates the inflammation caused by carrageenan in the mouse model of pleurisy.
- Author
-
Buss Zda S, Medeiros YS, and Fröde TS
- Subjects
- Adenosine Deaminase metabolism, Animals, Carrageenan, Cell Movement, Disease Models, Animal, Inflammation chemically induced, Inflammation pathology, Inflammation Mediators metabolism, Interleukin-17 metabolism, Interleukin-1beta metabolism, Leukocytes, Mononuclear metabolism, Mice, Peroxidase metabolism, Pleurisy chemically induced, Pleurisy immunology, Rosiglitazone, Tumor Necrosis Factor-alpha metabolism, Vascular Endothelial Growth Factor A metabolism, Inflammation drug therapy, PPAR gamma agonists, Pleurisy drug therapy, Thiazolidinediones pharmacology
- Abstract
The aim of this study was to investigate the anti-inflammatory efficacy of rosiglitazone (ROSI) in a pleurisy model of carrageenan-induced inflammation. Efficacy was monitored in the mouse pleural cavity by evaluating leukocyte migration, exudate concentration, and myeloperoxidase (MPO) and adenosine deaminase (ADA) activities concomitantly with nitrate/nitrite (NOx), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-17A (IL-17A), and vascular endothelial growth factor-alpha (VEGF-α) levels 4 and 48 h after pleurisy induction. In both phases (4 and 48 h) of pleurisy, ROSI inhibited all the inflammation parameters that were tested (p<0.05). These results provide evidence that ROSI was efficacious in inhibiting pro-inflammatory mediators. These anti-inflammatory effects are assumed to mainly result from the inhibition of products released from activated leukocytes, such as MPO, ADA, NOx, TNF-α, IL-1β, IL-17A, and VEGF-α.
- Published
- 2012
- Full Text
- View/download PDF